Onconetix, Inc. Files 8-K with Regulatory Updates

Ticker: ONCO · Form: 8-K · Filed: 2025-06-16T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-disclosure, financial-reporting

TL;DR

Onconetix (ONCO) filed an 8-K on 6/16/25 - check for updates.

AI Summary

Onconetix, Inc. filed an 8-K on June 16, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio.

Why It Matters

This filing provides important updates and disclosures for investors regarding Onconetix, Inc.'s regulatory compliance and financial reporting.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Numbers

Key Players & Entities

FAQ

What specific information is being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in this excerpt.

What financial statements and exhibits are included with this filing?

The filing states that Financial Statements and Exhibits are included, but the content of these documents is not detailed in the provided text.

When did Onconetix, Inc. change its name from Blue Water Biotech, Inc.?

The date of the name change from Blue Water Biotech, Inc. to Onconetix, Inc. was April 24, 2023.

What is the company's fiscal year end?

The company's fiscal year ends on December 31st.

What is the company's principal executive office address?

The principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.

From the Filing

0001213900-25-054501.txt : 20250616 0001213900-25-054501.hdr.sgml : 20250616 20250616084011 ACCESSION NUMBER: 0001213900-25-054501 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250616 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250616 DATE AS OF CHANGE: 20250616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Onconetix, Inc. CENTRAL INDEX KEY: 0001782107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41294 FILM NUMBER: 251048619 BUSINESS ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 BUSINESS PHONE: 513-620-4101 MAIL ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Biotech, Inc. DATE OF NAME CHANGE: 20230424 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Vaccines Inc. DATE OF NAME CHANGE: 20190710 8-K 1 ea0245818-8k_onconetix.htm CURRENT REPORT false 0001782107 0001782107 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): June 16, 2025   Onconetix, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-41294   83-2262816 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   201 E. Fifth Street , Suite 1900 Cincinnati , Ohio   45202 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 513) 620-4101   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.00001 per share   ONCO   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 7.01 Regulation FD Disclosure.   On June 16, 2025, Onconetix, Inc. (the “Company”) issued a press release announcing that it received a decision from the Nasdaq Hearings Panel granting the Company’s request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with certain Nasdaq Listing Rules on or before June 30, 2025. A copy of the press re

View on Read The Filing